Detecting inherited risk factors for diseases tied to more than a single gene has proved challenging. Now, researchers used artificial intelligence to predict an individual's risk for developing a complex cardiovascular disease using only his or her genome sequence.
On September 6 in the journal Cell, Stanford researchers describe a new personal health management tool dubbed HEAL (hierarchical estimate from agnostic learning). HEAL analyzed massive amounts of data from both genome sequences and electronic health records to devise a test to accurately diagnose 300 patients with abdominal aortic aneurysm (AAA). Tied to both genes and lifestyle, AAA is the 10th leading cause of death in Western countries, affecting mostly those over age 65.
HEAL may one day help diagnose, treat, and prevent diseases such as AAA, according to the study's authors. "For example, we know that smoking has a tremendous influence on AAA development," says co-author Philip S. Tsao, professor of medicine at Stanford University School of Medicine. "If you knew you had a genetic predilection for AAA, you would strongly be advised not to pick up a smoking habit."
Tsao says HEAL can also detect neurological diseases such as autism and schizophrenia as well as cardiovascular diseases and chronic diseases of aging. "Our study presents a new framework for disease genome analysis," he says.
Disease outcomes usually result from the combined effect of personal genomes and lifestyle, making it difficult to diagnose certain diseases early or predict an individual's prognosis, says co-author Michael Snyder, director of genomics and personalized medicine at Stanford. HEAL's integrative model identifies genome baselines for a given disease and provides actionable guidelines, he says.
HEAL may one day allow physicians or genetic specialists to confer remotely with patients about the patient's personal genetic makeup. "In the long run, the patient would not visit the office at all unless they need to," Snyder says. "They could mail in their saliva sample, get back their genome sequence, and get return of results through video teleconference."
HEAL would provide the physician with a "risk score" encompassing recommendations about treatment and lifestyle. Snyder cautioned that the risk scores do not mean that a person will definitely get a particular disease. "We need to educate both the physician and patient about that," he says.
Using machine learning, in which computers extrapolate results from data on their own, HEAL processed whole-genome sequencing data, physiological measurements from patients' clinical visits, and their smoking histories. The system analyzed 313 individuals with AAA and 161 control cases to identify 60 genes important for AAA. The results were later confirmed in human aortic tissues and mouse models.
"These 60 genes form the basis for a risk model for the disease," Snyder says. "It is now possible to determine a person's risk for AAA right from their genome sequence. This is important because the disease is irreversible, and most people discover they have AAA when their aorta bursts, which is usually lethal."
While widespread genome profiling holds tremendous promise in predicting and managing disease, sequencing the DNA of every individual at birth or later in life raises privacy concerns. "The genome data belongs to the person and it is up to them to decide how to share it," Snyder says. "If placed in a medical database, it should be secure."
This work was supported by the National Institutes of Health and the Veterans Affairs Office of Research and Development.
Cell, Li et al.: "Decoding the Genomics of Abdominal Aortic Aneurysm" https://www.cell.com/cell/fulltext/S0092-8674(18)30916-4
Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit: http://www.cell.com/cell. To receive Cell Press media alerts, contact email@example.com.